Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

T cells are important for controlling ovarian cancer (OC). We previously demonstrated that combinatorial use of a personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-specific T cells and prolonged OC survival. Here, w...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:NPJ Vaccines
Egile Nagusiak: Tanyi, Janos L., Chiang, Cheryl L.-L., Chiffelle, Johanna, Thierry, Anne-Christine, Baumgartener, Petra, Huber, Florian, Goepfert, Christine, Tarussio, David, Tissot, Stephanie, Torigian, Drew A., Nisenbaum, Harvey L., Stevenson, Brian J., Guiren, Hajer Fritah, Ahmed, Ritaparna, Huguenin-Bergenat, Anne-Laure, Zsiros, Emese, Bassani-Sternberg, Michal, Mick, Rosemarie, Powell, Daniel J., Coukos, George, Harari, Alexandre, Kandalaft, Lana E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7960755/
https://ncbi.nlm.nih.gov/pubmed/33723260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41541-021-00297-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak